Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. (COAG) priced its initial public offering on May 1, 2026 at $18.00 per share, raising $301.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $795.5M. WilmerHale advised the company and Goodwin Procter advised the underwriters.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, targeting patients with serious bleeding and thrombotic diseases, a broad group of conditions that carry a life-long burden for many patients.

Status

IPO

Ticker

COAG

Exchange

Nasdaq Global Select

Priced

May 1, 2026

IPO price

$18.00

Raised

$301.5M

Market cap at IPO price

$795.5M

First filed

Apr 10, 2026

Company counsel

WilmerHale

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.